Schizoaffective Disorder
Cluster Number:
Wiki Number: PW193
Diagnosis: Schizoaffective Disorder-Much of the Wikipedia article dealt with the validity of this particular diagnosis.
US Patients: 0.5-.0.8 (less than 1)% sometime in their lives
World Patients:
Sex Ratio: M;W+. More women in depressive; about even numbers in bipolar areas.
Age Onset: 30% between ages 25 and 35.
Brain Area: abnormal thoughts, unstable mood; psychotic symptoms for two weeks without any mood disorders. IT’s often misdiagnosed.
Symptoms: Bipolar has mania; hypomania and mixed episode vs. depressive only. May have hallucinations, delusions, disorganized speech and
Progression: thinking. May include audiotory hasllucinations.
Causes: Genetics under environmental stresses; age of the father at conception; pot and other substance abuses may be factors as well.
Medications: antipsychotics, mood stabilizers and antidepressants; electroconvulsive therapy for severe and resistant symptoms.
Therapies: Returning the patient to do the normal activities of life along with vocational rehabilitation.
Youtube Video:
Schizophrenia vs. Schizophreniform vs. Schizoid vs. Schizotypal
Amazon or Library Book: Schizoaffective Disorder
Click the book to link or order from Amazon.
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.03.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Medical, Psychiatric, and Sociodemographic Predictors of Clozapine Initiation at an Academic Medical Centerby Kathleen Shangraw on November 21, 2024
CONCLUSIONS: This is the first study to identify homelessness as a predictor against clozapine use, which raises important clinical and ethical considerations. Our findings also add to the literature on clozapine prescribing discrepancies among ethnic-minority patients. Overall, clozapine remains underutilized as the gold-standard treatment for treatment-resistant schizophrenia-spectrum disorders, reinforcing a need to improve evidence-based prescribing.
- Psychosis in Laurence-Moon Syndrome: A Case Reportby Nojoud Al Fareh on November 21, 2024
CONCLUSION: This case study provides valuable insights into the manifestations and management of psychosis in patients with LMS. A multidisciplinary approach involving psychiatry, neurology, endocrinology, and metabolic care is essential for comprehensive treatment. We recommend genetic testing and counseling for the patient's family, particularly during family planning, with non-invasive prenatal testing (NIPT) for siblings after marriage. Further research is needed to develop targeted...
- Phelan-McDermid Syndrome-associated Psychosis: A Systematic Reviewby Mark A Colijn on November 20, 2024
CONCLUSION: Psychotic presentations in Phelan-McDermid syndrome may qualitatively differ from schizophrenia. Although numerous antipsychotics may be efficacious in the treatment of Phelan-McDermid syndrome-associated psychosis, this review most importantly highlights the paucity of available high-quality evidence to guide treatment decisions in this respect, and as such indicates the need for more reports to be published.
- Caregiving burden, depression, and anxiety in informal caregivers of people with mental illness in China: a cross-sectional surveyby Hao Yao on November 20, 2024
CONCLUSION: Informal caregivers of PwMI in China experienced a high level of caregiving burden, depression, and anxiety. Urgent actions are needed to relieve caregiving burden, depression, and anxiety among informal caregivers of PwMI in China.